Teva Pharmaceutical Q3 2025 Earnings Preview

  • Teva Pharmaceutical (TEVA) is scheduled to announce Q3 earnings results on Wednesday, November 5th, before market open.
  • The consensus EPS Estimate is $0.67 (-2.9% Y/Y) and the consensus revenue estimate is $4.33B (+0.7% Y/Y).
  • Over the last 2 years, TEVA has beaten EPS estimates 75% of the time and has beaten revenue estimates 88% of the time.
  • Over the last 3 months, EPS estimates have seen 2 upward revisions and 4 downward. Revenue estimates have seen 1 upward revision and 5 downward.

Leave a Reply

Your email address will not be published. Required fields are marked *